Botanix Pharmaceuticals (ASX:BOT) is poised for a significant stock re-rating as it nears the full commercial launch of Sofdra, a prescription treatment for excessive underarm sweating, according to a Tuesday note by Euroz Harlteys.
Euroz Hartleys expects sales from the launch to push the stock above Botanix Pharmaceuticals' price target.
On Jan. 31, the company said that the full commercial launch of Sofdra is officially underway, with sales professionals set to hit the field within the next week.
Botanix Pharmaceuticals also said a digital launch of Sofdra is scheduled for the quarter.
Euroz noted that the company has completed agreements with all major health insurers in the US to ensure that Sofdra, will be covered under the insurers' plans.
The agreements will make Sofdra accessible to 167 million people who are covered by these insurers, Euroz added.
The company has also met the criteria for US government health programs, granting Sofdra access to an additional 80 million people starting in March.
Euroz Hartleys maintained Botanix Pharmaceuticals' buy rating and its price target of AU$0.55.
Shares of the company rose 5% at market close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。